The Top 5 Biosimilar Articles for the Week of May 3

Here are the top 5 biosimilar articles for the week of May 3, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of May 3, 2021.

Number 5: Representative Carolyn B. Maloney questions the use of pharmaceutical profits to defend against biosimilar competition in recent arguments before the House Subcommittee on Antitrust, Commercial, and Administrative Law.

Number 4: Biosimilars producers reported positive sales trends for biosimilars as the pandemic wears on and said patients still are not visiting doctors in the proportions they did before the start of the health crisis in early 2020.

Number 3: Biocon Biologics reported that their first-quarter revenues were up 26%, to $275.9 million, vs the comparable year-ago quarter, driven largely by the company's biosimilars, research services, and generics businesses.

Number 2: The results of the Voltaire-X trial could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.

Number 1: Two much-touted bills for biologics and biosimilar advancement were signed into law by President Joe Biden, but the devil is in the details, and whether they are going to have a tangible effect on biosimilar access is debatable.

To read all of these articles and more, visit centerforbiosimilars.com.